原发中枢神经系统淋巴瘤诱导后策略结局比较:梅奥诊所经验
该回顾性研究纳入2010年10月至2022年6月诊断的148例原发中枢神经系统淋巴瘤患者,比较接受大剂量甲氨蝶呤(HD-MTX)诱导后自体干细胞移植巩固(n=70)与HD-MTX维持治疗(n=37)的结局。中位随访4.5年,两组5年无进展生存率分别为74.6%和72.6%,总生存率分别为76.0%和82.4%,诱导后管理策略对无进展生存或总生存无显著差异。作者认为对诱导治疗有反应的患者,HD-MTX维持可能是合理且限时的治疗策略。
要点
- 148例原发中枢神经系统淋巴瘤患者接受HD-MTX诱导后,70例接受自体干细胞移植巩固,37例接受HD-MTX维持。
- 中位随访4.5年,自体移植组与维持组5年无进展生存率分别为74.6%和72.6%。
- 两组5年总生存率分别为76.0%和82.4%,诱导后管理策略对无进展生存或总生存无显著差异。
核心结论
- 诱导后管理策略(自体干细胞移植巩固与HD-MTX维持)对原发中枢神经系统淋巴瘤患者的无进展生存或总生存无显著差异。
- 作者认为对初始诱导治疗有反应的患者,HD-MTX维持可能是合理且限时的治疗策略。
研究设计与样本
- 回顾性研究,纳入2010年10月至2022年6月诊断的原发中枢神经系统淋巴瘤患者148例。
- 患者接受HD-MTX为基础的诱导治疗后,70例接受自体干细胞移植巩固,37例接受HD-MTX维持治疗。
主要发现
- 中位随访4.5年,无进展生存为8.3年,总生存未达到。
- 维持治疗组中位诊断年龄72岁,自体移植组62岁;维持组东部肿瘤协作组评分2分及以上比例41%,自体移植组29%,呈更高趋势。
- 诱导治疗开始后5年,自体移植组与维持组无进展生存率分别为74.6%和72.6%,总生存率分别为76.0%和82.4%。
临床怎么用
- 作者认为对初始诱导治疗有反应的原发中枢神经系统淋巴瘤患者,HD-MTX维持可能是合理且限时的治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma involving the brain, cerebrospinal fluid, or retina/vitreous without systemic involvement. Induction with high-dose methotrexate (HD-MTX) followed by consolidation with autologous stem cell transplant (auto-SCT) has become the standard treatment paradigm for most patients. However, limited data are available regarding the efficacy of a maintenance approach with HD-MTX. Herein, we retrospectively reviewed the characteristics and outcomes of 148 patients diagnosed with PCNSL between October 2010 and June 2022, who underwent HD-MTX-based induction therapy followed by either auto-SCT consolidation (n = 70) or HD-MTX maintenance therapy (n = 37). At a median follow-up time of 4.5 years, the progression-free survival (PFS) was 8.3 years and the overall survival (OS) was not reached. Compared to patients who underwent auto-SCT, patients who received maintenance HD-MTX had a higher median age at diagnosis of 72 vs 62 years and a trend toward higher proportion of patients being Eastern Cooperative Oncology Group 2 or higher (41% vs 29%). At 5-years postinduction treatment initiation, the PFS rates in the auto-SCT cohort and HD-MTX maintenance cohort were 74.6% and 72.6%, respectively, and the OS rates were 76.0% and 82.4%, respectively. Overall, there was no significant difference in PFS or OS based on postinduction management strategy. Our data suggest that maintenance HD-MTX may be a reasonable, time-limited treatment strategy for patients with PCNSL responding to initial induction therapy.
引用
- Hwang SR, Godby RC, Negaard BJ, et al. Comparison of outcomes in postinduction strategies for primary central nervous system lymphoma: a Mayo Clinic experience. Blood Adv. 2025. PMID: 39964705. doi:10.1182/bloodadvances.2024014073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。